[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Faivre-Finn C, Bouvier AM, Mitry E, Rassiat E, Clinard F, Faivre J: Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? Aliment Pharmacol Ther; 2002 Mar;16(3):353-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed?
  • BACKGROUND: It has been demonstrated that adjuvant chemotherapy in TNM stage III and palliative chemotherapy are effective treatments for colon cancer.
  • AIM: To determine changes over a 10-year period in the practice of adjuvant and palliative chemotherapy for colon cancer in a well-defined French population.
  • METHODS: Some 4093 patients with colon adenocarcinoma diagnosed between 1989 and 1998 were studied.
  • RESULTS: The proportion of patients with stage II disease treated with adjuvant chemotherapy increased from 2.3% (1989-90) to 20.5% (1997-98).
  • The use of palliative chemotherapy increased over time from 13.6% (1989-90) to 38.9% (1997-98).
  • CONCLUSIONS: The use of adjuvant chemotherapy has increased for stage II disease despite the absence of proven effectiveness.
  • Both adjuvant and palliative chemotherapy are still under-prescribed in patients over the age of 75 years.
  • [MeSH-major] Chemotherapy, Adjuvant / utilization. Colonic Neoplasms / drug therapy. Palliative Care / utilization
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. France. Humans. Logistic Models. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11876687.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Greene FL, Stewart AK, Norton HJ: A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg; 2002 Oct;236(4):416-21; discussion 421
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients.
  • OBJECTIVE: To analyze a large cohort of patients with stage III colon cancer to determine whether subgroup stratification better defines outcome.
  • SUMMARY BACKGROUND DATA: The Tumor (T), Node (N), Metastasis (M) system is based on depth of tumor invasion into the colonic wall, the number of regional lymph nodes involved, and distant metastasis.
  • Traditionally, colon cancer has been designated as stage III based on nodal involvement regardless of the depth (T1-4) of tumor penetration.
  • Treatment decisions have been based on nodal involvement with less emphasis on colonic wall penetration in stage III patients.
  • METHODS: Patients (n = 50,042) with stage III colon cancer reported to the National Cancer Data Base from 1987 through 1993 were analyzed.
  • RESULTS: Three distinct subcategories within a traditional stage III cohort of colonic cancer were identified.
  • Similar differences were calculated after stratification for treatment.
  • A multivariate proportional hazards model identified the new stage III subgroups, modality of the first course of therapy, patient age, and tumor grade as significant independent prognostic covariates.
  • CONCLUSIONS: The current stage III designation of colon cancer excludes prognostic subgroups stratified for mural penetration (T1-4) or nodal involvement (N1 vs. N2).
  • Analysis of a large data set supports stratification into three subsets, confirming the benefit of adjuvant chemotherapy in each subgroup.
  • This strategy should be used in the reporting and staging of node-positive colon cancers.
  • [MeSH-major] Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Outcome Assessment (Health Care) / statistics & numerical data. Registries / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Surg Gynecol Obstet. 1949 Mar;88(3):326-31 [18111779.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):685-7 [11041058.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):203-12 [11195411.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1350-7 [11350905.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):300-4 [11352302.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9 Suppl):94S-98S [11599912.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] World J Surg. 2002 Mar;26(3):384-9 [11865379.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1235-9 [3675187.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):918-26 [8756390.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1829-37 [8859199.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2296-304 [9404707.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2649-58 [9874473.001]
  • [Cites] Ann Surg. 1954 Jun;139(6):846-52 [13159135.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):601-8 [11005559.001]
  • (PMID = 12368669.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1422595
  •  go-up   go-down


3. Sadahiro S, Suzuki T, Ishikawa K, Yasuda S, Tajima T, Makuuchi H, Saitoh T, Murayama C: Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial. Cancer; 2004 Feb 1;100(3):590-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
  • BACKGROUND: The liver is the most frequent site of recurrence after curative resection in patients with colon carcinoma.
  • For liver metastasis, a high response rate can be achieved with hepatic arterial infusion (HAI) chemotherapy.
  • In the current study, the authors administered 5-fluorouracil (5-FU) as adjuvant chemotherapy by HAI to patients with colon carcinoma without liver metastases and studied its effects on recurrence in the liver and survival.
  • METHODS: A total of 316 patients with preoperative Stage II or Stage III colon carcinoma (according to the 1997 revision of the International Union Against Cancer TNM staging system) were randomly assigned to receive surgery plus 3-week continuous HAI of 5-FU or surgery alone.
  • RESULTS: There were no significant differences noted in morbidity between the two treatment arms.
  • CONCLUSIONS: A schedule of 3-week HAI of 5-FU given as adjuvant chemotherapy to patients with Stage III colon carcinoma appeared to contribute to a significant decrease in the frequency of liver metastases and was associated with an improved survival rate.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Fluorouracil / administration & dosage. Liver Neoplasms / prevention & control
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Chi-Square Distribution. Colectomy / methods. Combined Modality Therapy. Female. Follow-Up Studies. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Primary Prevention / methods. Probability. Reference Values. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • [CommentIn] Cancer. 2004 Feb 1;100(3):437-40 [14745858.001]
  • (PMID = 14745877.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Moug SJ, Saldanha JD, McGregor JR, Balsitis M, Diament RH: Positive lymph node retrieval ratio optimises patient staging in colorectal cancer. Br J Cancer; 2009 May 19;100(10):1530-3
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive lymph node retrieval ratio optimises patient staging in colorectal cancer.
  • Alternative lymph node (LN) parameters have been proposed to improve staging in colorectal cancer.
  • This study compared these alternative parameters with conventional TNM staging in predicting long-term survival in patients undergoing curative resection.
  • 10.4) underwent resection for colorectal cancer from 2001 to 2004.
  • Age, sex, primary tumour site, TNM stage and chemotherapy/radiotherapy were recorded.
  • Patients with colon and rectal cancers were analysed separately for LN parameters: LN total; adequate LN retrieval (> or =12) and inadequate (<12); total number of negative LN; total number of positive LN and the ratio of positive LN to total LN (pLNR).
  • On multivariate analysis, only pLNR was an independent predictor of overall survival in both colon and rectal cancers (HR 11.65, 95% CI 5.00-27.15, P<0.001 and HR 13.40, 95% CI 3.64-49.10, P<0.001, respectively).
  • Application of the pLNR improved patient stratification in colorectal cancer and should be considered in future staging systems.
  • [MeSH-major] Carcinoma / pathology. Colorectal Neoplasms / pathology. Lymph Node Excision. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Sep;7(8):838-81 [19755047.001]
  • [Cites] Dis Colon Rectum. 1994 Apr;37(4):373-6; discussion 376-7 [8168417.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3570-5 [16877723.001]
  • [Cites] Gut. 2006 Nov;55(11):1681 [17047131.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):543-52 [17414602.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Acta Oncol. 2007;46(7):975-81 [17917828.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):365-71 [18216546.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • (PMID = 19401684.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2696755
  •  go-up   go-down


5. Liang JT, Lai HS, Lee PH: Laparoscopic medial-to-lateral approach for the curative resection of right-sided colon cancer. Ann Surg Oncol; 2007 Jun;14(6):1878-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic medial-to-lateral approach for the curative resection of right-sided colon cancer.
  • INTRODUCTION: Our previous randomized clinical trial comparing the laparoscopic medial-to-lateral dissection with the more classic lateral-to-medial approach for resection of rectosigmoid cancer showed that the medial approach reduces the operative time and the postoperative proinflammatory response.
  • Besides the oncologic advantages of an early vessel division and a "no-touch" dissection, we feel that the longer the lateral abdominal wall attachments of the colon are preserved, the better the exposure and the easier the dissection.
  • Encouraged by the above-mentioned positive findings, we therefore further conduct this phase II clinical trial to examine the feasibility and surgical outcomes regarding the utilization of this medial-to-lateral laparoscopic dissection approach for the curative resection of right-sided colon cancer.
  • METHODS: A total of 104 patients (from December 2000 to January, 2005) with advanced right-sided colon cancer (TNM stage II: n = 56; stage III: n = 48) requiring a curative right hemicolectomy were subjected to the laparoscopic medial-to-lateral approach that included initial exploration and ligation of ileocolic, right colic, and middle colic vessels in no-touch isolation fashion, subsequent medial-to-lateral extension of retroperitoneal dissection along Gerota fascia, opening of lesser sac by transection of gastrocolic ligament, and the final mobilization of hepatic flexure and lateral attachments of ascending colon (Fig. 1).
  • Postoperatively, adjuvant chemotherapy with Mayo Clinic Regimen was given in patients with stage III diseases.
  • RESULTS: The laparoscopic medial-to-lateral approach for a curative right hemicolectomy can be preformed with acceptable operation time (192.6 +/- 32.8 min, mean +/- standard deviation) and little blood loss (48.4 +/- 14.4 ml) through a small wound (6.0 +/- 0.8 cm).
  • During the follow-up periods (median: 30 months, range 6-55 months), recurrence of tumor developed in 6 (10.7%) of stage II and 10 (20.8%) of stage III patients, with liver metastasis in six patients, lung metastasis in 4, liver and lung metastasis in 1, intraperitoneal recurrence in 2, bone metastasis in 1, brain metastasis in 1, and port-site recurrence in 1.
  • [MeSH-major] Colectomy / methods. Colon, Ascending / surgery. Colonic Neoplasms / surgery. Laparoscopy / methods
  • [MeSH-minor] Blood Loss, Surgical. Chemotherapy, Adjuvant. Dissection / methods. Feasibility Studies. Follow-Up Studies. Hospitalization. Humans. Ileus / etiology. Ligaments / surgery. Ligation. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Pain, Postoperative / etiology. Postoperative Complications. Prospective Studies. Recovery of Function / physiology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17377832.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Higashi D, Ishibashi Y, Tamura T, Nii K, Egawa Y, Koga M, Tomiyasu T, Harimura T, Tanaka R, Futatsuki R, Noda S, Futami K, Maekawa T, Takaki Y, Hirai F, Matsui T: Clinical features of and chemotherapy for cancer of the small intestine. Anticancer Res; 2010 Aug;30(8):3193-7
Genetic Alliance. consumer health - Small intestine cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of and chemotherapy for cancer of the small intestine.
  • BACKGROUND: Cancer of the small intestine is a rare disease, and its clinical features have not been clearly elucidated.
  • Techniques such as double balloon endoscopy and capsule endoscopy allow the preoperative diagnosis of cancer of the small intestine, but this cancer is often detected at an advanced state and in many cases postoperative chemotherapy is required.
  • This study evaluated the pre- and postoperative clinical course of cancer of the small intestine and the effectiveness of chemotherapy.
  • PATIENTS AND METHODS: Patients who underwent surgery for cancer of the small intestine in this Department from July 1985 to December 2008 were included in this study.
  • Duodenal cancer has vastly different origins, methods of diagnosis, and surgical procedures, so this form of cancer was excluded.
  • There were 8 cases of jejunal or ileal cancer treated during the study period.
  • The pre- and postoperative course of these cases was reviewed, as well as the effectiveness of chemotherapy in cases of recurrence.
  • Six patients underwent a partial resection of the small intestine, and a right hemicolectomy, and a bypass were performed in one case each.
  • The tumor type according to Borrmann's classification indicated that 5 tumors were type 2, 2 were type 3, and 1 was type 5; the mean tumor size was 6.3±5.3 (2.5-18.0) cm.
  • TNM staging indicated that 3 tumors were stage II, 1 was stage III, and 4 were stage IV.
  • Six patients underwent postoperative chemotherapy.
  • One patient underwent adjuvant chemotherapy of, and 5 patients with recurring or advanced cancer underwent therapeutic chemotherapy of.
  • The course of chemotherapy for the 5 patients with recurrent or advanced cancer resulted in 4 patients with progressive disease (PD) and 1 with stable disease (SD).
  • CONCLUSION: The basic treatment for cancer of the small intestine is surgical resection.
  • Palliative surgery and chemotherapy are considered in cases where resection is not possible or the cancer recurs.
  • Nevertheless, there is no established regimen for such chemotherapy.
  • Cancer of the small intestine is currently being treated with chemotherapy based on the treatment strategies for colon cancer, but there are few reports of its success.
  • Chemotherapy was unsuccessful in treating any of the patients with recurring or advanced cancer reviewed in this report.
  • The diagnosis must therefore be improved and postoperative chemotherapy will be needed to treat cancer of the small intestine given its increasing incidence, and therefore physicians are working as quickly as possible to establish an optimal treatment regimen.
  • [MeSH-major] Intestinal Neoplasms / drug therapy. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871040.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Spano JP, Bouillet T, Morere JF, Breau JL: [The interest of radiotherapy in cancer of the rectum]. Presse Med; 2003 Feb 22;32(7):315-22
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The interest of radiotherapy in cancer of the rectum].
  • [Transliterated title] Intérêt de la radiothérapie dans le cancer du rectum.
  • CONTEXT: Surgery remains the standard treatment of rectal cancer.
  • This depends on the initial TNM stage and the surgical technique.
  • In order to optimally improve local control and survival of the patients, radiotherapy has become an unavoidable adjuvant treatment in specific situations.
  • ISOLATED RADIOTHERAPY: For locally advanced cancers (T3 or T4), pre-surgical radiotherapy followed by curative surgery is the standard treatment because of the improvement in global survival and good local control that has recently been confirmed.
  • THE CONCOMITANT ASSOCIATION OF RADIOTHERAPY AND CHEMOTHERAPY DURING THE PRE-SURGICAL PERIOD: In rare cases in which the tumour stage was underestimated in the pre-surgical controls, post-surgical concomitant radio-chemotherapy is required.
  • In cases in which surgery was performed first line, in the presence of histological factors of poor prognosis, post-surgical radio-chemotherapy is warranted.
  • In the United States, the reference chemotherapy used in this association is 5 FU in continuous intravenous infusion.
  • In the rare cases of contraindication for surgery, exclusive concomitant radio-chemotherapy is an appropriate solution, even if no treatment has been validated in this indication.
  • MEDICAL TREATMENT: Exclusive radio-chemotherapy has only demonstrated interest in the palliative treatment of inoperable loco-regional relapses that have already undergone radiation or in metastatic stages as in colon cancers.
  • Currently post-surgical chemotherapy is recommended in stage III cancer of the rectum as in colon cancers at the same stage.
  • [MeSH-major] Neoadjuvant Therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Neoplasm Staging. Palliative Care. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12610448.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J: Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer; 2007 Mar 15;109(6):1082-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
  • BACKGROUND: The MOSAIC trial demonstrated that oxaliplatin/5-fluorouracil/leucovorin (FU/LV) (FOLFOX4) as adjuvant treatment of TNM stage II and III colon cancer significantly improves disease-free survival compared with 5-FU/LV alone.
  • CONCLUSIONS: FOLFOX4 is likely to be cost-effective compared with 5-FU/LV in the adjuvant treatment of stage III colon cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / economics. Colonic Neoplasms / drug therapy. Organoplatinum Compounds / economics
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / economics. Cost-Benefit Analysis. Female. Fluorouracil / administration & dosage. Fluorouracil / economics. Humans. Leucovorin / administration & dosage. Leucovorin / economics. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Survival Analysis. United States

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17265519.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Park CM, Lee WY, Chun HK, Cho YB, Yun HR, Heo JS, Yun SH, Kim HC: Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy. J Surg Oncol; 2010 Jan 1;101(1):22-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
  • BACKGROUND: The aim of this study was to determine whether the different polymorphisms in the thymidylate synthase (TS) gene, novel G>C single nucleotide polymorphism (SNP) and variable number of tandem repeat (VNTR), may be related with disease-free survival (DFS) in patients with stage III colorectal cancer receiving adjuvant chemotherapy.
  • METHODS: The study included 201 patients with pathologic TNM stage III colon cancer who received adjuvant 5-fluorouracil (5-FU)-based chemotherapy after surgery.
  • DNA was extracted from fresh tumor tissue and sequenced.
  • RESULTS: Frequencies of the TS tandem repeat polymorphisms among the tumor genotypes were 6.0% in 2R2R, 25.4% in 2R3R, and 68.7% in 3R3R.
  • In multivariate analysis, only tumor stage showed significant prognostic value (hazard ratio (HR) 2.05, 95% CI = 1.24-3.37, P = 0.005).
  • CONCLUSIONS: TS polymorphisms do not predict clinical outcome of colorectal cancer patients treated with adjuvant 5-FU-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / genetics. Minisatellite Repeats. Polymorphism, Single Nucleotide. Thymidylate Synthase / genetics
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Genotype. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19798689.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Bamias A, Basdanis G, Xanthakis I, Pavlidis N, Fountzilas G: Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis of two randomized studies. Int J Gastrointest Cancer; 2005;36(1):29-38
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis of two randomized studies.
  • BACKGROUND: Although the TNM system is useful in predicting survival in resected colorectal cancer, heterogeneity within the same stages regarding prognosis exists.
  • We are presenting a pooled analysis of prognostic factors from two randomized studies of adjuvant treatment conducted by the Hellenic Cooperative Oncology Group.
  • PATIENTS AND METHODS: Patients with stage II or III colon (n = 279) or rectal (n = 220) cancer were included in this analysis.
  • The number of involved lymph nodes (LNs), tumor differentiation, and the presence of regional implants were independent prognostic factors for both OS and TTP, while nerve invasion was only significant for TTP.
  • CONCLUSION: The combination of clinicopathological prognostic factors can be more informative than the traditional TNM staging system.
  • Such stratification may be necessary in randomized trials and could be useful in deciding the most appropriate adjuvant treatment strategies.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Interferon-alpha / administration & dosage. Leucovorin / administration & dosage. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Recombinant Proteins. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Oncology. 2000 Apr;58(3):227-36 [10765125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1859-61 [2004298.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):671-6 [10442189.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):202-19 [11198882.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2406-8 [15175443.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1128-32 [15292384.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1778-84 [14769855.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1785-96 [15067027.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):698-702 [4041728.001]
  • (PMID = 16227633.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 47RRR83SK7 / interferon alfa-2a; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Saigí E, Musulén E, García-García Y, Bombardó J, Nogué M, Seguí MA, Fernández-Morales L, Martinez-Peralta S, Rey M, Pericay C: Study of survival in non metastatic surgical colon cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):3750

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of survival in non metastatic surgical colon cancer.
  • : 3750 Background: Colon cancer is the second neoplasm in men and women.
  • Its prognostic depends on TNM staging at diagnosis.
  • The treatment seems to improve the survival.
  • The aim of this study is to analyze our series of surgical colon cancer from 1996 to 2001.
  • METHODS: We analyzed 422 surgical colon cancer.
  • 70 patients were metastatic at the time of diagnosis or behind surgery (5 months).
  • The prognosis factors were: age at diagnosis, gender, locations in the large bowel, kind of surgery, pT, pN, stage, use of chemotherapy, disease free survival (DFS) and overall survival (OS).
  • RESULTS: The 352 non metastatic surgical colon cancer presented a mean age at diagnosis of 70,22 years (24 to 101).
  • 145 patients received adjuvant chemotherapy.
  • CONCLUSIONS: The main prognostic factor for survival in colon cancer was the staging at diagnosis.
  • Patients with pT4 or pN2 should received aggressive treatments for the high risk of metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA; 2008 Jan 30;299(4):425-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.
  • CONTEXT: MicroRNAs have potential as diagnostic biomarkers and therapeutic targets in cancer.
  • No study has evaluated the association between microRNA expression patterns and colon cancer prognosis or therapeutic outcome.
  • OBJECTIVE: To identify microRNA expression patterns associated with colon adenocarcinomas, prognosis, or therapeutic outcome.
  • DESIGN, SETTING, AND PATIENTS: MicroRNA microarray expression profiling of tumors and paired nontumorous tissues was performed on a US test cohort of 84 patients with incident colon adenocarcinoma, recruited between 1993 and 2002.
  • We evaluated associations with tumor status, TNM staging, survival prognosis, and response to adjuvant chemotherapy.
  • MAIN OUTCOME MEASURES: MicroRNAs that were differentially expressed in tumors and microRNA expression patterns associated with survival using cancer-specific death as the end point.
  • Higher miR-21 expression was present in adenomas (P = .006) and in tumors with more advanced TNM staging (P < .001).
  • The 5-year cancer-specific survival rate was 57.5% for the Maryland cohort and was 49.5% for the Hong Kong cohort.
  • High miR-21 expression was associated with poor survival in both the training (hazard ratio, 2.5; 95% confidence interval, 1.2-5.2) and validation cohorts (hazard ratio, 2.4; 95% confidence interval, 1.4-3.9), independent of clinical covariates, including TNM staging, and was associated with a poor therapeutic outcome.
  • CONCLUSIONS: Expression patterns of microRNAs are systematically altered in colon adenocarcinomas.
  • High miR-21 expression is associated with poor survival and poor therapeutic outcome.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Pharmacogenomics J. 2007 Oct;7(5):297-304 [17189960.001]
  • [Cites] Cell. 2003 Apr 4;113(1):25-36 [12679032.001]
  • [Cites] Curr Biol. 2003 Apr 29;13(9):790-5 [12725740.001]
  • [Cites] Mol Cancer Res. 2003 Oct;1(12):882-91 [14573789.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] J Mol Biol. 2004 May 28;339(2):327-35 [15136036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Stat Med. 1985 Jan-Mar;4(1):87-90 [3992076.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Cell. 1993 Dec 3;75(5):855-62 [8252622.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Nature. 2005 Dec 1;438(7068):685-9 [16258535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92 [16505370.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Arch Med Res. 2006 May;37(4):548-51 [16624657.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):2113-29 [16762633.001]
  • [Cites] Mol Cancer. 2006;5:29 [16854228.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18680-4 [17121985.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Jan;36(1):8-12 [16917074.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):976-83 [17283129.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):29-46 [17311531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] JAMA. 2007 May 2;297(17):1901-8 [17473300.001]
  • [Cites] JAMA. 2007 May 2;297(17):1923-5 [17473304.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [CommentIn] JAMA. 2008 Jun 11;299(22):2628; author reply 2628-9 [18544721.001]
  • (PMID = 18230780.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 BC005480-22
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN21 microRNA, human; 0 / MicroRNAs; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS82855; NLM/ PMC2614237
  •  go-up   go-down


13. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA: The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol; 2007;29(5):387-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.
  • BACKGROUND: Tumor staging insufficiently discriminates between colon cancer patients with poor and better prognosis.
  • We have evaluated, for the primary tumor, if the carcinoma-percentage (CP), as a derivative from the carcinoma-stromal ratio, can be applied as a candidate marker to identify patients for adjuvant therapy.
  • METHODS: In a retrospective study of 63 patients with colon cancer (stage I-III, 1990-2001) the carcinoma-percentage of the primary tumor was estimated on routine H&E stained histological sections.
  • Additionally these findings were validated in a second independent study of 59 patients (stage I-III, 1980-1992). (None of the patients had received preoperative chemo- or radiation therapy nor adjuvant chemotherapy.
  • High levels of significance were found (OS p<0.0001, DFS p<0.0001) with hazard ratio's of 3.73 and 4.18.
  • In a multivariate Cox regression analysis, CP remained an independent variable when adjusted for either stage or for tumor status and lymph-node status (OS p<0.001, OS p<0.001).
  • CONCLUSIONS: The carcinoma-percentage in primary colon cancer is a factor to discriminate between patients with a poor and a better outcome of disease.
  • This parameter is already available upon routine histological investigation and can, in addition to the TNM classification, be a candidate marker to further stratify into more individual risk groups.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Lymph Nodes / pathology. Stromal Cells / pathology
  • [MeSH-minor] Aged. Demography. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Microsatellite Instability. Neoplasm Staging. Proportional Hazards Models. Reproducibility of Results

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726261.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4617992
  •  go-up   go-down


14. Czito BG, Hong TJ, Cohen DP, Tyler DS, Lee CG, Anscher MS, Ludwig KA, Seigler HF, Mantyh C, Morse MA, Lockhart AC, Petros WP, Honeycutt W, Spector NL, Ertel PJ, Mangum SG, Hurwitz HI: A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):779-85
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
  • We addressed the safety of oral eniluracil and 5-FU combined with preoperative radiotherapy and determined the recommended Phase II dose and dose-limiting toxicity in patients with locally advanced rectal and colon cancer.
  • METHODS AND MATERIALS: Patients with TNM Stage II or III rectal cancer and residual or recurrent colon cancer received eniluracil (starting at 6.0 mg/m(2) every 12 h) and 5-FU (starting at 0.6 mg/m(2) every 12 h).
  • Chemotherapy was completed in all patients; radiotherapy was completed in 20 patients.
  • Eleven of the 17 patients with primary rectal cancer underwent a sphincter-sparing procedure.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / adverse effects. Colonic Neoplasms / drug therapy. Colonic Neoplasms / radiotherapy. Enzyme Inhibitors / administration & dosage. Fluorouracil / adverse effects. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Uracil / adverse effects. Uracil / analogs & derivatives
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967434.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Enzyme Inhibitors; 2E2W0W5XIU / eniluracil; 56HH86ZVCT / Uracil; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, McMillan DC: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer; 2007 Nov 5;97(9):1266-70
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer.
  • There is increasing evidence that the presence of a systemic inflammatory response plays an important role in predicting survival in patients with colorectal cancer.
  • The aim of the present study was to compare the prognostic value of an inflammation-based prognostic score (modified Glasgow Prognostic Score (Mgps) 0=C-reactive protein <10 mg l(-1), 1=C-reactive protein >10 mg l(-1), and 2=C-reactive protein >10 mg l(-1) and albumin<35 g l(-1)) with that of components of the white cell count (neutrophils, lymphocytes, monocytes and platelets using standard thresholds) in patients with colorectal cancer.
  • Two patient groups were studied: 149 patients who underwent potentially curative resection for colorectal cancer and 84 patients who had synchronous unresectable liver metastases.
  • In those patients who underwent potentially curative resection the minimum follow-up was 36 months and 20 patients died of their cancer.
  • On multivariate survival analysis only TNM stage (HR 3.75, 95% CI 1.54-9.17, P=0.004), monocyte count (HR 3.79, 95% CI 1.29-11.12, P=0.015) and mGPS (HR 2.21, 95% CI 1.11-4.41, P=0.024) were independently associated with cancer-specific survival.
  • In patients with synchronous unresectable liver metastases the minimum follow-up was 6 months and 71 patients died of their cancer.
  • On multivariate survival analysis only single liver metastasis >5 cm (HR 1.78, 95% CI 0.99-3.21, P=0.054), extra-hepatic disease (HR 2.09, 95% CI 1.05-4.17, P=0.036), chemotherapy treatment (HR 2.40, 95% CI 1.82-3.17, P<0.001) and mGPS (HR 1.44, 95% CI 1.01-2.04, P=0.043) were independently associated with cancer-specific survival.
  • In summary, markers of the systemic inflammatory response are associated with poor outcome in patients with either primary operable or synchronous unresectable colorectal cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Inflammation Mediators / metabolism
  • [MeSH-minor] Aged. Female. Humans. Leukocyte Count. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):861-8 [10737287.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):881-6 [17245566.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):617-23 [11005561.001]
  • [Cites] Ann Intern Med. 2000 Oct 17;133(8):622-34 [11033592.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):331-5 [11875693.001]
  • [Cites] Br J Surg. 2002 May;89(5):586-90 [11972548.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):64-9 [12094630.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):215-9 [12555298.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1028-30 [12966420.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1704-6 [15150622.001]
  • [Cites] Cancer. 1970 Jan;25(1):135-40 [5410303.001]
  • [Cites] JAMA. 1982 Feb 19;247(7):1004-6 [7035703.001]
  • [Cites] J R Coll Surg Edinb. 1998 Jun;43(3):163-8 [9654876.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):64-70 [9671068.001]
  • [Cites] Am J Surg. 1998 Oct;176(4):335-8 [9817250.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):448-54 [9971870.001]
  • [Cites] J Surg Oncol. 2005 Sep 1;91(3):181-4 [16118772.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6240-8 [16135490.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):227-30 [16404432.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):637-41 [16479253.001]
  • [Cites] Support Care Cancer. 2006 Oct;14(10):999-1011 [16708213.001]
  • [Cites] Pancreatology. 2006;6(5):450-3 [16847382.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):205-12 [17149754.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):222-5 [17211465.001]
  • [Cites] J Support Oncol. 2007 Apr;5(4):157-62; discussion 164-6, 183 [17500503.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):83-91 [10813129.001]
  • (PMID = 17923866.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Inflammation Mediators
  • [Other-IDs] NLM/ PMC2360467
  •  go-up   go-down


16. Lo DS, Pollett A, Siu LL, Gallinger S, Burkes RL: Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer. Cancer; 2008 Jan 1;112(1):50-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer.
  • BACKGROUND: Tumor nodules are occasionally found in adjacent mesentery of colorectal cancer specimens and are felt to reflect a worse prognosis.
  • The clinical significance of mesenteric tumor nodules was investigated.
  • METHODS: A review of 786 patients with stage III colorectal cancer referred between 1995 and 1999 was undertaken.
  • TNM staging was standardized by considering mesenteric nodules separately and not assigning them to T or N categories.
  • RESULTS: Mesenteric tumor nodules were found in 116 (14.8%) patients: 48 (41.4%) with colon cancer and 68 (58.6%) rectal cancer.
  • Adjuvant chemotherapy was given to 84.8% of colon cancer patients.
  • Two (2.9%) rectal cancer patients received neoadjuvant chemoradiation, and 63 (92.6%) received adjuvant therapy (chemotherapy and/or radiation).
  • In the cohort with mesenteric nodules, the median time to progression was 23.1 months, the median 5-year disease-free survival was 35%, and the median overall survival (OS) was 47.9 months, with 44% OS at 5 years.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 18008365.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ju JH, Chang SC, Wang HS, Yang SH, Jiang JK, Chen WC, Lin TC, Hung Hsu, Wang FM, Lin JK: Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years. Int J Colorectal Dis; 2007 Aug;22(8):855-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years.
  • BACKGROUND AND AIMS: Colorectal cancer (CRC) is the third most common cause of cancer-related death in Taiwan.
  • During the past 20 years, several advances have improved the treatment outcome and quality of life of CRC patients.
  • MATERIALS AND METHODS: Based on the computerized database of the Taipei Veterans General Hospital, between January 1981 and December 2000, 5,474 CRC patients were identified and divided into 2 groups based on the date of treatment (1981-1990 and 1991-2000).
  • RESULTS/FINDINGS: The age at onset of cancer was 61 years in the 1980s group and 66 years in the 1990s group.
  • Tumor, nodes, metastasis (TNM) stage distribution, surgical mortality, and anastomosis leakage were similar in the two groups.
  • For rectal cancer patients, the local recurrence rate was lower in the 1990s group (6%) than that in the 1980s group (10%, P < 0.01).
  • TNM stage was the most important independent prognostic factor for overall and disease-free survivals, followed by differentiation grade, CEA level, and treatment period.
  • INTERPRETATION/CONCLUSION: Advances in surgical technique and more standard use of chemotherapy have improved CRC outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / mortality. Colorectal Neoplasms / therapy. Digestive System Surgical Procedures. Quality of Life
  • [MeSH-minor] Age of Onset. Aged. Carcinoembryonic Antigen / blood. Cell Differentiation. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Medical Records Systems, Computerized. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Recurrence. Taiwan / epidemiology. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1192-202 [11870160.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3992-8 [12351596.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Dis Colon Rectum. 1978 Apr;21(3):169-71 [206417.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):899-906 [8143995.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6 Suppl 11):S14-23 [17178280.001]
  • [Cites] JAMA. 2005 Dec 7;294(21):2703-11 [16333005.001]
  • [Cites] Br J Surg. 1983 Mar;70(3):150-4 [6831156.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):395-9 [12598344.001]
  • [Cites] Br J Surg. 1998 Apr;85(4):515-20 [9607537.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):179-82 [1434643.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] Br J Surg. 2003 May;90(5):583-92 [12734867.001]
  • [Cites] Jpn J Cancer Res. 1990 Jan;81(1):100-4 [2108942.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 21;84(20):1572-5 [1404450.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):653-7 [1736103.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Dis Colon Rectum. 2002 Oct;45(10):1393-6 [12394441.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1482-6 [9554524.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):721-5 [12679919.001]
  • [Cites] Gut. 1999 Mar;44(3):377-81 [10026324.001]
  • [Cites] Oncologist. 2006 Oct;11(9):1018-24 [17030644.001]
  • [Cites] N Engl J Med. 1994 Apr 21;330(16):1136-42 [8133857.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):14-20 [7677801.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):10-7 [12422309.001]
  • [Cites] JAMA. 1993 Mar 10;269(10):1278-81 [8437306.001]
  • [Cites] Br J Surg. 1989 Nov;76(11):1165-7 [2688803.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1293-300 [12663717.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 1):14-9 [11273584.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):465-9 [15729069.001]
  • [Cites] Dis Colon Rectum. 2005 Oct;48(10):1858-65; discussion 1865-7 [16086223.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):319-22 [15637735.001]
  • [Cites] Semin Oncol. 2003 Jun;30(3 Suppl 6):39-50 [12802794.001]
  • (PMID = 17390145.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


18. Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M: Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum; 2004 Nov;47(11):1798-807
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
  • PURPOSE: The aim of this study was to evaluate factors associated with pathologic tumor response following pre-operative chemoradiation therapy, and the prognostic impact of pathologic response on overall and disease-free survival.
  • METHODS: Between 1994 and 2002, 132 patients underwent chemoradiation therapy followed by surgery for middle to lower rectal cancer.
  • After excluding 26 cases (metastatic cancer, n = 13; nonradical surgery, n = 6; local excision procedure, n = 4; non-5-fluorouracil-based chemotherapy, n = 2; incomplete data on preoperative chemoradiation therapy regimen used, n = 1), the remaining 106 patients were included in the study.
  • Variables considered were the following: age, gender, tumor location, pretreatment T and N stage, modality of 5-fluorouracil administration, total radiotherapy dose delivered, chemoradiation therapy regimen used (Regimen A: chemotherapy (bolus of 5-fluorouracil and leucovorin, days 1-5 and 29-33) + radiotherapy (45 Gy/25 F/1.8 Gy/F); Regimen B: chemotherapy (5-fluorouracil continuous venous infusion +/- weekly bolus of carboplatin or oxaliplatin) + radiotherapy (50.4 Gy/28 F/1.8 Gy/F)), time interval between completion of chemoradiation therapy and surgery, postoperative chemotherapy administration, surgical procedures, pT, pN, and pTNM stage, and response to chemoradiation therapy defined as tumor regression grade, scored from 1 (no tumor on surgical specimen) to 5 (absence of regressive changes).
  • Median distance of tumor from the anal verge was 6 (range, 1-11) cm.
  • Pretreatment TNM stage, available in 104 patients, was cT3T4N0, n = 41; cT2N1, n = 9; cT3N1, n = 39; and cT4N1, n = 17.
  • The median radiotherapy dose delivered was 50.4 (range, 40-56) Gy; 58 patients received 5-fluorouracil by continuous venous infusion, and carboplatin with oxaliplatin was added to the chemotherapy schedule in 71 cases.
  • The median interval between chemoradiation therapy and surgery was 42.5 (range, 19-136) days, and 94 patients underwent a sphincter-saving procedure.
  • Tumor regression grade, available in 104 cases, was 1, n = 19; 2, n = 18; 3, n = 15; 4, n = 13; and 5, n = 39.
  • At logistic regression analysis, the chemoradiation therapy regimen used was the only independent predictor of tumor response following preoperative chemoradiation therapy (odds ratio = 0.29, 95% confidence interval = 0.13-0.67, P = 0.003).
  • CONCLUSIONS: Tumor response following preoperative chemoradiation therapy is mainly related to the preoperative regimen used.
  • For patients receiving preoperative chemoradiation therapy, pretreatment T stage, but not tumor response to preoperative chemoradiation therapy, is prognostic for outcome (both disease-free and overall survival).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chi-Square Distribution. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Logistic Models. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622571.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; BG3F62OND5 / Carboplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Zhao DB, Gao JD, Shan Y, Zhou ZX, Yuan XH, Wu JX, Shao YF: [Characteristics of metastasis and recurrence following curative resection for colonic carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul;9(4):291-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The clinicopathological and follow-up data of 310 patients with colon carcinoma undergoing curative resection were analyzed retrospectively.
  • Gross classification,histological type, differentiation, lymph node metastasis were correlated with metastasis/recurrence.
  • Univariate analysis revealed that gross classification, histological type, differentiation, lymph node metastasis, blood vessel invasion, TNM Stage, postoperative chemotherapy, portal chemotherapy were prognostic factors.
  • Cox regression analysis revealed that only gross classification, lymph node metastasis, postoperative chemotherapy, portal chemotherapy were independent prognostic factors.
  • Gross classification, lymph node metastasis, postoperative chemotherapy, and portal chemotherapy are independent prognostic factors.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886105.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC: [Clinicopathologic characteristics of colorectal neuroendocrine tumor]. Korean J Gastroenterol; 2006 Aug;48(2):97-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics of colorectal neuroendocrine tumor].
  • BACKGROUND/AIMS: Colorectal neuroendocrine carcinoma is a rare neoplasm exhibiting fulminant progression and having poor prognosis.
  • RESULTS: Ten patients (0.2%) with colorectal neuroendocrine tumors were identified from 4,512 patients with colorectal cancer; ten neuroendocrine carcinomas and three adenocarcinomas with neuroendocrine differentiation.
  • Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse colon and cecum, respectively.
  • All patients were advanced at the time of diagnosis, with AJCC TNM staging: stage IIIB (n=2), stage IIIC (n=3), and stage IV (n=8).
  • Five patients who received chemotherapy showed median survival of 32 months (stage III) and 17.5 months (stage IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
  • Nevertheless, improved survival may be achieved by aggressive multimodality therapy.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929153.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


21. Vogelsang H, Siewert JR: Endocrine tumours of the hindgut. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):739-51
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer.
  • Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy.
  • Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy.
  • It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery.
  • [MeSH-minor] Anastomosis, Surgical. Biopsy, Needle. Colonoscopy / methods. Female. Humans. Incidence. Male. Neoplasm Staging. Prognosis. Rare Diseases. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253898.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


22. Belt EJ, van Stijn MF, Bril H, de Lange-de Klerk ES, Meijer GA, Meijer S, Stockmann HB: Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III. Ann Surg Oncol; 2010 Dec;17(12):3203-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node negative colorectal cancers with isolated tumor deposits should be classified and treated as stage III.
  • BACKGROUND: The prognostic role of pericolic or perirectal isolated tumor deposits (ITDs) in node-negative colorectal cancer (CRC) patients is unclear.
  • Rules to define ITDs as regional lymph node metastases changed in subsequent editions of the TNM staging without substantial evidence.
  • CONCLUSIONS: Because of the high risk of disease recurrence, all node-negative stage II patients with ITDs, regardless of size and shape, should be classified as stage III, for whom adjuvant chemotherapy should be considered.
  • [MeSH-major] Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 May 15;88(10):2228-38 [10820343.001]
  • [Cites] Arch Surg. 2001 Feb;136(2):216-20 [11177145.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Dis Colon Rectum. 2002 Jun;45(6):733-42; discussion 742-3 [12072622.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1531-7 [14605575.001]
  • [Cites] Gut. 2007 Oct;56(10):1419-25 [17494107.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):31-8 [7821914.001]
  • [Cites] Surg Today. 1997;27(7):617-22 [9306563.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):55-61 [9510311.001]
  • [Cites] Surg Today. 2005;35(5):377-84 [15864419.001]
  • [Cites] Histopathology. 2007 Aug;51(2):141-9 [17532768.001]
  • [Cites] Hum Pathol. 1994 May;25(5):498-505 [8200644.001]
  • (PMID = 20625841.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2995864
  •  go-up   go-down


23. Georgescu SO, Neacşu CN, Vintilă D, Popa P, Forţu L, Nistor A, Ferariu D, Târcoveanu E: [Long-term results after surgery for colorectal adenocarcinoma, stage I-III. Problems of prognosis]. Rev Med Chir Soc Med Nat Iasi; 2007 Oct-Dec;111(4):932-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer is one of the leading causes of cancer-related death worldwide.
  • STUDY DESIGN: Prospective study on 142 consecutively cases with stage I to III colorectal adenocarcinomas (TNM AJCC/UICC) in which patients underwent potentially curative surgery in one single public health service (1st Surgical Clinic Iaşi, Romania) between 2004 and 2005.
  • The surgical procedures performed were the following: right colectomy (n = 54; 30%); transverse colectomy (n = 2; 1.4%); left colectomy (n = 19; 13.4%); segmental colon resection with anastomosis (n = 5 ; 3.5%); Hartmann procedure (n = 18; 12.7%); anterior rectal resection (n = 11; 7.7%) and abdominoperineal resection (n = 33; 23.2%).
  • With regard to postoperative adjuvant therapy most patients were given chemotherapeutic agents such as 5-fluorouracil and folinic acid.
  • RESULTS: The factors with a significant negative influence in overall survival and 42-months survival rates were: the age over 70 years, the emergency surgery related to cancer's complications, the advanced AJCC/ UICC stage, vascular invasion, perineural invasion, the recurrence of disease, the moderate and lower differentiated adenocarcinoma and incomplete or not performed chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / mortality. Prognosis. Prospective Studies. Romania. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389783.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


24. Yang SH, Lee RC, Chen CC, Jiang JK, Lin JK, Li AF, Liang WY, Wang LW: Is decrease of tumor volume correlated with stage change after preoperative concurrent chemoradiotherapy? Hepatogastroenterology; 2005 May-Jun;52(63):765-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is decrease of tumor volume correlated with stage change after preoperative concurrent chemoradiotherapy?
  • BACKGROUND/AIMS: The significance of tumor volume and its change after concurrent chemoradiotherapy (CCRT) was evaluated.
  • Volume of tumor calculated from images obtained by dynamic MRI of the rectum before and after CCRT was compared to pathological results after definite resection and other clinical data.
  • RESULTS: The T-stage in 15 patients (50%), the N-stage in 13 (72.2%), and overall, the TNM stage in 18 (60%), were downstaged, including 7 (23.3%) with complete responses (CR).
  • Volume of tumor before CCRT (Vpre) and after CCRT (VPost) was 10.3+/-6.1cm3 and 4.2+/-2.2cm3, respectively, and VPre correlated with initial T stage, N stage, age, and location.
  • The net decrease ratio (NDR) of tumor volume was related to Vpre and initial T stage.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Neoadjuvant Therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prodrugs / therapeutic use. Rectum / pathology. Treatment Outcome. Uracil / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966201.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Prodrugs; 56HH86ZVCT / Uracil; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement